Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-Line Drugs: A Nation-Wide Population-Based Comparative Safety Study.

Huan WangRuth L M CordinerYu HuangLouise DonnellySimona HapcaAndrew CollierJohn McKnightBrian KennonFraser W Gibb Paul M McKeigue Sarah D Wild Helen Martina ColhounJohn ChalmersJohn R Petrie Naveed SattarThomas MacDonaldRory J McCrimmonDaniel R MoralesEwan R Pearsonnull null

Published in: Diabetes care (2023)

Our findings contribute to the understanding that second-line SU for glucose lowering are unlikely to increase CV risk or all-cause mortality. Given their potent efficacy, microvascular benefits, cost effectiveness, and widespread use, this study supports that SU should remain a part of the global diabetes treatment portfolio.

Keyphrases

type diabetes
cardiovascular disease
glycemic control
metabolic syndrome
adipose tissue
blood glucose